2020 ASCO Virtual Scientific Meeting*

May 29-31, 2020; Online at meetings.asco.org/am
Review slidesets and expert analyses of key data from the 2020 Clinical Oncology Virtual Scientific Meeting!

Breast and Gynecologic Cancers

Capsule Summary Slidesets

Adding pembrolizumab to chemotherapy improves PFS in mTBC with PD-L1 CPS 10 or higher

Released: June 1, 2020

Addition of veliparib to cisplatin improved median PFS by 47% compared with cisplatin and placebo in gBRCA-negative metastatic TNBC patients with BRCA-like phenotype.

Released: June 4, 2020

Tucatinib plus trastuzumab/capecitabine demonstrated statistically significant and clinically meaningful improvements in intracranial response rate, CNS-PFS, and OS in patients with brain metastases.

Released: June 2, 2020

Alpelisib plus fulvestrant demonstrated clinically meaningful efficacy based on the proportion of patients alive without PD at 6 months in this analysis of patients with PIK3CA-mutated HR+/HER2- advanced BC previously treated with CDK4/6i plus AI.

Released: June 3, 2020

In this pooled analysis of ctDNA from 3 MONALEESA breast cancer studies, multiple potential biomarkers of ribociclib sensitivity and resistance were identified.

Released: May 31, 2020

Ribociclib plus ET associated with prolonged OS and PFS in patients with HR+/HER2- breast cancer and visceral metastases.

Released: June 3, 2020

Ribociclib plus letrozole appears safe and effective as first-line endocrine therapy in an expanded patient population with HR+, HER2- advanced breast cancer regardless of menopausal status.

Released: June 1, 2020

Secondary cytoreductive surgery with complete resection in patients with platinum-sensitive recurrent ovarian cancer and a positive AGO Score leads to substantial improvement in survival outcomes.

Released: June 3, 2020

Maintenance olaparib increased median OS by more than 1 year vs placebo and was well tolerated over prolonged treatment duration.

Released: June 1, 2020

Pembrolizumab monotherapy resulted in ORR of 8.5% with median DoR of 10.2 mos and median OS of 18.7 mos in patients with advanced recurrent ovarian cancer.

Released: June 8, 2020

In this updated analysis, niraparib plus bevacizumab prolonged PFS and time to subsequent therapies over niraparib alone in patients with platinum-sensitive recurrent ovarian cancer.

Released: June 8, 2020

Individualized dosing of niraparib based on weight and platelet count improves tolerability with no loss of efficacy.

Released: June 1, 2020

Lenvatinib plus pembrolizumab showed promising efficacy as early-line treatment for patients with advanced endometrial cancer that is not MSI-H or dMMR in this post hoc analysis of KEYNOTE-146.

Released: June 5, 2020

Addition of early local therapy to systemic therapy for intact primary tumors in patients with de novo MBC was not associated with a survival benefit vs continued systemic therapy alone.

Released: June 9, 2020
Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp
Novartis Pharmaceuticals Corporation

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?